Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Williams, Briana Jill ^a   Bhatia, Shilpa ^a   Adams, Lisa K ^a   Boling, Susan ^a   Carroll, Jennifer L ^a   Li, Xiao Lin ^a   Rogers, Donna L ^a   Korokhov, Nikolay ^b   Kovesdi, Imre ^b   Pereboev, Alexander V ^c   Curiel, David T ^d   Mathis, J Michael ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VectorLogics Inc   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR VACCINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TARGET CELL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, SURFACE; ATP-BINDING CASSETTE TRANSPORTERS; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; DENDRITIC CELLS; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84867301359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046981     Document Type: Article

References (26)

1. Siegel R, Ward E, Brawley O, Jemal A Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Di Lorenzo G, Buonerba C, Kantoff PW Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8: 551-561.
3. Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 11: 997-1009.
4. Ghosh A, Heston WD, (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91: 528-539.
5. Doehn C, Bohmer T, Kausch I, Sommerauer M, Jocham D, (2008) Prostate cancer vaccines: current status and future potential. BioDrugs 22: 71-84.
6. Olson WC, Heston WD, Rajasekaran AK, (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2: 182-190.
7. Fishman M, (2009) A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 9: 1565-1575.
8. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Bohme C, et al. (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55: 1524-1533.
9. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, et al. (2006) Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66: 811-821.
10. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG, (2008) Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 8: 865-874.
11. Bolhassani A, Safaiyan S, Rafati S Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10: 3.
12. Rein DT, Breidenbach M, Curiel DT, (2006) Current developments in adenovirus-based cancer gene therapy. Future Oncol 2: 137-143.
13. Stockwin LH, Matzow T, Georgopoulos NT, Stanbridge LJ, Jones SV, et al. (2002) Engineered expression of the Coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer. J Immunol Methods 259: 205-215.
14. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, et al. (2004) Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 9: 712-720.
15. Brandao JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, et al. (2003) CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 21: 2268-2272.
16. Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T,et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 71: 5827-5837.
17. Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R,et al. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother 33: 706-715.
18. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC, (1995) Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52: 403-413.
19. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514.
20. Li XL, Zhang D, Knight D, Odaka Y, Glass J, et al. (2009) Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming. Immunology 128: 420-428.
21. Izumi M, Kawakami Y, Glasgow JN, Belousova N, Everts M, et al. (2005) In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med 7: 1517-1525.
22. Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG, (2002) Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate 53: 183-191.
23. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G,et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28: 3548-3557.
24. Procko E, Gaudet R, (2009) Antigen processing and presentation: TAPping into ABC transporters. Curr Opin Immunol 21: 84-91.
25. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, et al. (2005) Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207: 19-30.
26. Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, et al. (2003) IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Molecular Therapy: the Journal of the American Society of Gene Therapy 7: 185-192.